ACTIVATION AND REGULATION OF THE HER2 AND HER4 KINASES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 信号转导通路的改变在人类肿瘤的生长和转移中起着重要作用。我们关注的是Her2/neu受体酪氨酸激酶，它是EGFR生长因子受体家族的成员，在大约25%的人类乳腺癌病例中，它是基因扩增和激活的。针对Her2/neu的几种药物被用于治疗Her2阳性乳腺癌，例如针对受体胞外部分的单抗或小分子激酶抑制剂，但患者经常对这些药物产生耐药性。更好地了解Her2/neu及其使用的下游信号转导通路将为乳腺癌患者提供更好的治疗。 我们的实验室使用生物化学、蛋白质组学和细胞生物学等多种方法研究乳腺癌中的信号转导途径。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Alterations of signal transduction pathways play a significant role in the growth and metastasis of human cancers. We focus on the Her2/neu receptor tyrosine kinase, a member of the EGFR growth factor receptor family, which is gene amplified and activated in about 25% of human breast cancer cases. Several drugs that target Her2/neu are used in the treatment of Her2-positive breast cancer, such as a monoclonal antibody to the extracellular portion of the receptor or small molecule kinase inhibitors, but resistance to these drugs has frequently been seen in patients. Better understanding of Her2/neu and the downstream signal transduction pathways it uses will provide improved treatment for breast cancer patients. Our lab studies signal transduction pathways in breast cancer using a variety of approaches involving biochemistry, proteomics, and cell biology.